drugset / Trial / NCT02254070

Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

NCT02254070 ↗

Phase 1 Completed 23 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the influence of different degrees of renal impairment on safety, tolerability, pharmacodynamics and pharmacokinetics of 1.0 mg of BIBT 986 BS given as a single dose infusion over 30 minutes in comparison to a normal renal function

Timeline

Start
2003-06
Primary completion
2004-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBT 986 BS Unknown 1 mg —

Indications

No indication recorded.